Tiffany reported its first rise in sales in eight quarters as strong sales in China and Japan more than offset a decline in the U.S. » Read More
UnitedHealth said it expected to earn between $9.30 and $9.60 per share in 2017, excluding items. » Read More
Dollar Tree's shares gained 8.16 percent on Tuesday, closing at $88.68. » Read More
Wal-Mart's U.S. comparable sales came in just shy of what analysts were expecting, at 1.2 percent growth.
Best Buy reported better-than-expected comparable-store sales, helped by higher demand for consumer electronics and mobile phones.
First Solar forecast sales well below estimates, and said it would slash about 1,600 jobs as it transitions to a new product ahead of schedule.
Cisco's earnings challenges will subside as new growth opportunities emerge in the U.S. and worldwide tensions ease, CEO Chuck Robbins says.
Target saw a boost in traffic and sales trends during the fiscal third quarter.
Lowe's CEO Robert Niblock says store traffic slowed more than anticipated in August and September.
Tencent posted a lower-than-expected rise in profit as expenses for media and advertising took a bite out of its strong revenue growth.
Shares of Dick's Sporting Goods fell nearly 8 percent on Tuesday after the company released its third quarter earnings report.
TJX, operator of off-price retailers T.J. Maxx and HomeGoods, reported better-than-expected quarterly comparable store sales as its discounted offerings continue to attract shoppers.
The home improvement retailer's same-store sales also topped expectations.
JD.com, China's second-largest e-commerce firm, said on Tuesday its third-quarter revenue grew 38 percent from a year ago.
JC Penney reported a drop in same=store sales, reflecting weak store traffic, increased competition and a general shift away from apparel spending.
Macy's reaffirmed its previous earnings-per-share guidance, and raised its sales outlook for the full year.
Shares of Ralph Lauren traded more than 3 percent higher early Thursday following the report.
Kohl's also reaffirmed its full-year earnings-per-share guidance of $3.80 to $4, excluding items such as store closings.
Valeant Pharmaceuticals reported an 11 percent fall in quarterly revenue due to faltering sales, and cut its full-year profit and revenue forecasts.
Get the best of CNBC in your inbox